SOHO ANNUAL MEETING 2024

The First Results of Ruxolitinib Versus Best Available Therapy for Polycythemia Vera in Mongolia

Chinbat.G[1] ,Baljinnyam.P[1], Myadagsuren.S[1], Elbegjargal.E[1], Bulgan.D[1], Nansalmaa.A[1], Oyundelger.N
[1]The First Central Hospital of Mongolia

THE FIRST CENTRAL HOSPITAL OF MONGOLIA 1925

INTRODUCTION

Polycythemia Vera is characterized by JAK/STAT activation, thrombotic events, symptoms, and disease transformation. In high risk PV, Ruxolitinib controls blood counts and improves symptoms.

AIM

To evaluate results of patients with Polycythemia Vera between JAK and BAT therapy for 6 months in Mongolia.

METHOD

This retrospective cohort study included 41 patients with Polycythemia Vera in Mongolia. We divided participants into two group that followed receiving Ruxolitnib versus the BAT. Differences between the groups were analyzed using correlated and uncorrelated t-tests, with statistical significance set at $p < 0.05$.

RESULTS

At 3 months, the hematological parameters for the Ruxolitinib group were: WBC - 12.2 ± 6.39 (p = 0.11), Hematocrit (HCT) - 41.67 ± 10.05 (p = 0.05), Hemoglobin (HGB) - 13.47 ± 3.05 (p = 0.03), and Platelet count (PLT) - 425 ± 225 (p = 0.8). For the BAT group, the parameters were: WBC - 11.64 ± 7.03 (p = 0.49), HCT - 51.29 ± 7.22 (p = 0.02), HGB - 16.9 ± 2.3 (p = 0.01), and PLT - 543 ± 308 (p = 0.5).
At 6 months, the hematological parameters for the ruxolitinib group were: WBC - 11.14 ± 4.29 (p = 0.03), HCT - 37.9 ± 8.4 (p = 0.0014), HGB - 12.41 ± 2.51 (p = 0.0009), and PLT - 374 ± 203 (p = 0.21). For the BAT group, the parameters were: WBC - 11.62 ± 6.25 (p = 0.29), HCT - 49.02 ± 6.94 (p = 0.0001), HGB - 16.4 ± 2.08 (p = 0.0002), and PLT - 494 ± 198 (p = 0.74).

The recommended font for captions is Calibri, not smaller than 15 pt. Left aligned if it refers to a figure on its left. Try to start the captions right at the top edge of the picture (graph or photo).

The recommended font for captions is Calibri, not smaller than 15 pt. Left aligned if it refers to a figure on its left. Try to start the captions right at the top edge of the picture (graph or photo).

CONCLUSIONS

The mean age was 58.8±11.0 years, including 17 men and 24 women. Of the 41 cases, 20 patients (48.8%) had JAK, 21 (51.2%) had BAT.

REFERENCES

Vannucchi, Alessandro M., et al. "Ruxolitinib versus standard therapy for the treatment of polycythemia vera." *New England Journal of Medicine* 372.5 (2015): 426-435.

Mora, Maria Meritxell Roca, et al. "Ruxolitinib Versus Best Available Therapy for Polycythemia Vera: A Systematic Review and Meta-Analysis." *Blood* 142 (2023): 6428.

ACKNOWLEDGEMENTS

The support and time of participating patients and their families is gratefully acknowledged.

CONTACT INFORMATION

Telephone: +976 96338845

E-mail: chinbat.g@fchm.edu.mn